CVRx (NASDAQ:CVRX) Major Shareholder Sells $534,309.72 in Stock

CVRx, Inc. (NASDAQ:CVRX) major shareholder & Johnson Johnson sold 52,332 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $10.21, for a total value of $534,309.72. Following the completion of the sale, the insider directly owned 4,051,098 shares of the company’s stock, valued at approximately $41,361,710.58. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

& Johnson Johnson also recently made the following trade(s):

• On Friday, November 7th, & Johnson Johnson sold 200 shares of CVRx stock. The shares were sold at an average price of $10.00, for a total value of $2,000.00.

CVRx Stock Down 0.4%

Shares of NASDAQ CVRX traded down $0.04 during mid-day trading on Monday, reaching $9.67. The company had a trading volume of 235,419 shares, compared to its average volume of 291,692. The stock has a fifty day moving average of $8.74 and a two-hundred day moving average of $7.57. CVRx, Inc. has a 12-month low of $4.30 and a 12-month high of $18.55. The company has a market capitalization of $252.89 million, a price-to-earnings ratio of -4.60 and a beta of 1.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99.

CVRx (NASDAQ:CVRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The company had revenue of $14.69 million during the quarter, compared to the consensus estimate of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts expect that CVRx, Inc. will post -1.91 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on CVRX. Canaccord Genuity Group boosted their target price on CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of CVRx in a research note on Thursday, October 30th. Finally, Cantor Fitzgerald raised their price objective on shares of CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.17.

Institutional Investors Weigh In On CVRx

Large investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC bought a new position in shares of CVRx in the first quarter valued at approximately $28,000. Mount Lucas Management LP bought a new position in CVRx in the 2nd quarter worth $30,000. Intech Investment Management LLC acquired a new position in CVRx during the 2nd quarter worth $59,000. Whittier Trust Co. bought a new stake in CVRx during the first quarter valued at about $73,000. Finally, AlphaQuest LLC grew its position in shares of CVRx by 725.4% in the first quarter. AlphaQuest LLC now owns 6,108 shares of the company’s stock valued at $75,000 after purchasing an additional 5,368 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.